Who Owns Haohai Biological Technology Company?

Haohai Biological Technology Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Haohai Biological Technology?

Understanding the ownership structure of a company is paramount for investors and strategists alike. The evolution of a company's ownership reveals critical insights into its strategic direction and potential for growth. This analysis dives deep into the ownership of Haohai Biological Technology SWOT Analysis, a leading biotechnology firm, to uncover the key players shaping its future.

This exploration of Haohai Biological Technology's ownership will examine the initial investors, the current Haohai shareholders, and the impact of its dual listing on its ownership dynamics. We will also investigate the Haohai management and the influence of public shareholders. By analyzing the history of Haohai Biological Technology ownership, we aim to provide a comprehensive understanding of who controls this influential company and its strategic implications.

The story of Shanghai Haohai Biological Technology Co., Ltd. begins in January 2007 with the establishment of its predecessor, Haohai Limited, within the PRC. This marked the initial step in the company's journey, setting the stage for its future growth and development in the biotechnology sector. Understanding the founders and early ownership structure is crucial for grasping the company's foundational strategy and its subsequent evolution.

The initial capital and strategic direction were shaped by key individuals who laid the groundwork for what would become a significant player in the medical and biotechnology fields. The early ownership and investment decisions reflect the company's initial focus and the vision of its founders. The company's history showcases how strategic decisions and investments in the early stages influenced its trajectory.

The company's foundation was built upon an initial registered capital of RMB 20,000,000. Haohai Limited's ownership was primarily held by Haohai Chemical, with a 90% stake, and Mr. Jiang Wei, who held the remaining 10%. Mr. Jiang Wei's experience in the chemical manufacturing industry, dating back to 2000, provided the initial capital for the company's establishment. This early structure set the stage for the company's future development and expansion.

Key Founders and Early Ownership

Mr. Wu Jianying played a crucial role in the company's early development, contributing significantly to its strategic direction. In 2007, Mr. Wu and his team facilitated the merger and acquisition of three state-owned companies specializing in medical sodium hyaluronate. This strategic move was aimed at building a stronger competitive advantage. Mr. Wu Jianying personally invested in the company, including selling personal assets to fund the venture. This early investment underscores the commitment of key figures to the company's long-term success.

• By December 2, 2008, a shareholders' meeting approved a capital increase of RMB 47,578,700, raising the total share capital to RMB 120,000,000.
• Following the second capital increase, Haohai Chemical held 94.17% of Haohai Limited, while Mr. Jiang Wei held 5.83%.
• Other early Haohai shareholders included Ms. You Jie (24.00%), Mr. Lou Guoliang (8.33%), Mr. Hou Yongtai (5.00%), Mr. Huang Ming (1.67%), Mr. Liu Yuanzhong (1.67%), and Mr. Shen Rongyuan (1.67%).
• The early ownership structure reflects the strategic vision and financial commitment of the founders and early investors, setting the stage for the company's growth. For more insights, you can explore the Growth Strategy of Haohai Biological Technology.

Haohai Biological Technology SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Shanghai Haohai Biological Technology Co., Ltd. has evolved significantly since its transformation into a joint-stock company. The company's initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited (HKSE) on April 30, 2015, marked a pivotal moment, followed by a listing on the Sci-tech Innovation Board of the Shanghai Stock Exchange (SSE) on October 30, 2019. These listings expanded the shareholder base and provided access to capital markets. As of June 10, 2025, the total number of shares in issue is 233,193,695, with 194,051,855 A shares (83.215%) and 39,141,840 H shares (16.785%).

The company's ownership structure reflects a blend of founder control and institutional investment. Mr. Jiang Wei and his spouse, Ms. You Jie, are the ultimate controlling stakeholders. Several institutional investors also hold significant stakes in Haohai Biological Technology, including Prudence Investment Management (Hong Kong) Ltd., GF Fund Management Co., Ltd., and China Southern Asset Management Co., Ltd. These institutional investors play a crucial role in the company's governance and strategic direction. Significant share repurchases and capital structure adjustments further demonstrate the company's commitment to enhancing shareholder value. The company's share repurchases and capital structure adjustments demonstrate a commitment to optimizing capital structure and enhancing shareholder value.

The ownership of Haohai Biological Technology showcases a dynamic landscape, combining founder control with institutional investment. Understanding the evolution of Haohai ownership and the roles of major shareholders and investors is crucial for anyone interested in the company. For more insights into the competitive landscape, consider exploring the Competitors Landscape of Haohai Biological Technology.

Key Takeaways on Haohai Ownership

The ownership structure of Haohai Biological Technology involves founder control and significant institutional investor participation.

• The founders, Mr. Jiang Wei and Ms. You Jie, maintain ultimate control.
• Major institutional investors include Prudence Investment Management and GF Fund Management.
• The company has undertaken share repurchases and capital adjustments to enhance shareholder value.
• The total shares in issue as of June 10, 2025, are 233,193,695.

Haohai Biological Technology PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of June 10, 2025, the Board of Directors of Shanghai Haohai Biological Technology includes a mix of executive, non-executive, and independent non-executive directors. Dr. Hou Yongtai serves as the Executive Chairman. The executive directors are Dr. Hou Yongtai, Mr. Wu Jianying (also the General Manager), Ms. Chen Yiyi, and Mr. Tang Minjie (also the Chief Financial Officer). Ms. You Jie and Mr. Huang Ming are non-executive directors. The independent non-executive directors are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, and Mr. Yang Yushe. Ms. You Jie, the spouse of Mr. Jiang Wei, represents a major shareholder and holds positions on the Audit Committee, Nomination Committee, and chairs the Strategy and Sustainable Development Committee.

The company's governance structure includes several board committees. The Audit Committee members are Mr. Shen Hongbo (Chairman), Ms. You Jie, Mr. Jiang Zhihong, Mr. Su Zhi, and Mr. Zhao Lei. The Remuneration and Appraisal Committee consists of Mr. Su Zhi (Chairman), Mr. Wu Jianying, Mr. Huang Ming, Mr. Shen Hongbo, and Mr. Zhao Lei. The Nomination Committee members are Mr. Jiang Zhihong (Chairman), Dr. Hou Yongtai, Ms. You Jie, Mr. Shen Hongbo, and Mr. Su Zhi. The Strategy and Sustainable Development Committee is chaired by Ms. You Jie, with Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, and Mr. Yang Yushe as members.

The ultimate controlling stakeholders, Mr. Jiang Wei and Ms. You Jie, hold significant influence due to their combined ownership, impacting Haohai ownership and the company's strategic direction. The average tenure of the Haohai management team is 10.4 years, and the board of directors has an average tenure of 11.5 years, suggesting experienced leadership. Recent reports from May 2025 indicate an investigation into one of the ultimate controllers for suspected insider trading, potentially affecting decision-making. Furthermore, the company eliminated its Supervisory Committee on June 10, 2025, transferring its powers to the Audit Committee.

Key Takeaways on Haohai Biological Technology

This analysis of Haohai Biological Technology reveals key aspects of its leadership and governance structure. The board includes experienced directors, with significant influence from major shareholders. Understanding these dynamics is crucial for Haohai investors and stakeholders.

• The board of directors is composed of executive, non-executive, and independent non-executive directors.
• The ultimate controlling shareholders, Mr. Jiang Wei and Ms. You Jie, have significant influence.
• The company's governance structure includes various board committees.
• Recent events, such as an insider trading investigation, could impact the company's governance. For more insights, consider exploring the Marketing Strategy of Haohai Biological Technology.

Haohai Biological Technology Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent years have seen significant shifts in the ownership structure of Haohai Biological Technology. From March 2020 to the end of 2023, the company repurchased a substantial number of H shares, totaling 10,446,700, with 7,150,200 of these subsequently canceled. This trend continued into 2024, with additional H share repurchases and cancellations, alongside A share buybacks from August to December 2024. These actions, including a planned repurchase of up to 10% of H shares by June 2025, indicate a proactive approach to managing capital and enhancing shareholder value for Haohai shareholders.

Simultaneously, Haohai Biological Technology has also issued new shares. In March 2024, shares were issued under the 2021 Restricted A Share Incentive Scheme. A significant capital increase occurred in June 2024 through the transfer of capital reserve, leading to a 35.99% increase in share capital for the year. These strategic moves, combined with acquisitions like the 51% stake in Shanghai Shenhao Eyehealth Technology Development Co., Ltd., and the full acquisition of Endymed Ltd., reflect the company’s evolving ownership landscape and strategic growth initiatives, as well as the interest of Haohai investors.

The company's commitment to innovation is evident in its R&D spending, which increased by approximately 8.56% to RMB 238.93 million in 2024, representing 8.92% of revenue. For further insights into the company's business model and revenue streams, see Revenue Streams & Business Model of Haohai Biological Technology. Despite industry challenges, Haohai management remains focused on growth, with a final dividend of RMB 0.60 per share for 2024, payable on July 18, 2025.

Share Repurchases

The company actively repurchased both H and A shares to optimize its capital structure and increase shareholder value. This demonstrates a commitment to returning value to Haohai investors.

Share Issuance

New shares were issued under incentive schemes and through capital reserve transfers, reflecting strategic moves to support growth and development. This is an important part of the Haohai ownership.

Strategic Investments

Acquisitions, such as the stake in Shanghai Shenhao Eyehealth, highlight the company's expansion efforts within the medical beauty sector. These actions are overseen by Haohai management.

R&D Focus

Increased R&D spending underscores the company's commitment to innovation and the development of new products, such as topical botulinum toxin and hair loss treatments, which are important for Haohai company.

Haohai Biological Technology Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs